HER2+ advanced breast cancer: primary results from the phase 3 MARIANNE study

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, trastuzumab emtansine (T-DM1; Kadcycla) with or without pertuzumab (Perjeta) was noninferior in efficacy, but more tolerable than taxane plus trastuzumab (Herceptin).
Why this matters
  • T-DM1 with or without ...